Terns Pharmaceuticals (TERN) Competitors $7.99 -0.44 (-5.22%) Closing price 04:00 PM EasternExtended Trading$7.99 0.00 (0.00%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. OGN, MLYS, ALVO, IBRX, BHC, CPRX, TARS, IDYA, BEAM, and CDTXShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Organon & Co. (OGN), Mineralys Therapeutics (MLYS), Alvotech (ALVO), ImmunityBio (IBRX), Bausch Health Cos (BHC), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Beam Therapeutics (BEAM), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors Organon & Co. Mineralys Therapeutics Alvotech ImmunityBio Bausch Health Cos Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences Beam Therapeutics Cidara Therapeutics Organon & Co. (NYSE:OGN) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Does the media prefer OGN or TERN? In the previous week, Organon & Co. and Organon & Co. both had 4 articles in the media. Organon & Co.'s average media sentiment score of 1.44 beat Terns Pharmaceuticals' score of 0.09 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Terns Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OGN or TERN more profitable? Organon & Co. has a net margin of 11.15% compared to Terns Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 163.88% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.11.15% 163.88% 6.99% Terns Pharmaceuticals N/A -27.35%-26.18% Do analysts recommend OGN or TERN? Organon & Co. currently has a consensus target price of $17.33, indicating a potential upside of 63.57%. Terns Pharmaceuticals has a consensus target price of $15.49, indicating a potential upside of 93.84%. Given Terns Pharmaceuticals' higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Terns Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Do institutionals and insiders have more ownership in OGN or TERN? 77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 1.4% of Organon & Co. shares are held by company insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, OGN or TERN? Organon & Co. has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Which has preferable valuation and earnings, OGN or TERN? Organon & Co. has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.43$864M$2.693.94Terns PharmaceuticalsN/AN/A-$88.85M-$1.04-7.68 SummaryOrganon & Co. beats Terns Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$699.21M$3.32B$6.11B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-7.6821.6185.6926.92Price / SalesN/A424.41583.01184.15Price / CashN/A46.3226.3031.10Price / Book1.9610.0613.246.71Net Income-$88.85M-$52.22M$3.30B$276.35M7 Day Performance6.39%5.87%4.64%3.10%1 Month Performance10.66%12.07%8.36%10.19%1 Year Performance1.78%26.14%87.97%40.37% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals3.8526 of 5 stars$7.99-5.2%$15.49+93.8%+1.9%$699.21MN/A-7.6840Positive NewsOGNOrganon & Co.4.7837 of 5 stars$10.35+1.3%$17.33+67.6%-40.7%$2.65B$6.40B3.854,000Positive NewsMLYSMineralys Therapeutics3.2505 of 5 stars$39.35-1.6%$43.50+10.5%+173.8%$2.65BN/A-11.0528Positive NewsALVOAlvotech3.9909 of 5 stars$8.40+0.7%$14.00+66.7%-30.2%$2.51B$560.10M36.521,032News CoverageIBRXImmunityBio2.693 of 5 stars$2.57+1.2%$10.75+318.3%-26.2%$2.40B$14.74M-5.35590BHCBausch Health Cos4.7181 of 5 stars$6.47-0.2%$9.00+39.1%-22.1%$2.40B$9.63B24.8920,700CPRXCatalyst Pharmaceuticals4.8601 of 5 stars$19.55+0.2%$33.20+69.8%+3.7%$2.39B$491.73M11.8580Analyst DowngradeBuyback AnnouncementTARSTarsus Pharmaceuticals0.7768 of 5 stars$58.08+3.2%$66.67+14.8%+99.8%$2.38B$182.95M-24.9350IDYAIDEAYA Biosciences4.1821 of 5 stars$27.19+1.3%$43.36+59.5%-8.3%$2.35B$7M-7.1780BEAMBeam Therapeutics2.8925 of 5 stars$23.91+4.1%$46.40+94.1%+10.6%$2.32B$63.52M-5.31510CDTXCidara Therapeutics3.8767 of 5 stars$95.26+5.3%$119.43+25.4%+784.9%$2.29B$1.27M-8.5690High Trading Volume Related Companies and Tools Related Companies Organon & Co. Competitors Mineralys Therapeutics Competitors Alvotech Competitors ImmunityBio Competitors Bausch Health Cos Competitors Catalyst Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors IDEAYA Biosciences Competitors Beam Therapeutics Competitors Cidara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
